Exercise of Options, Director/PDMR Dealing & TVR

RNS Number : 7242L

Instem plc

05 January 2023

 

Instem plc

("Instem" or "the Company")

Exercise of Options, Director/PDMR Dealing and Total Voting Rights

Instem plc (AIM: INS), a leading provider of IT solutions to the global life sciences market, announces that it was notified on 4 January 2023 that certain of the Company's Directors and members of its senior management team exercised share options ("Share Options") over, in aggregate, 61,404 ordinary shares of 10 pence each in the Company ("Ordinary Shares"). The Share Options were exercised on 4 January 2023 at an exercise price of £0.90 per Ordinary Share.  The Share Options were granted on 14 January 2013 and would have lapsed if not exercised before 14 January 2023.

Subsequently, also on 4 January 2023, certain Directors sold the Ordinary Shares issued on the exercise of Share Options in their entirety at a price of £7.00 per Ordinary Share.

Details of the Directors (each of whom is a person discharging managerial responsibility or "PDMR") who exercised Share Options and subsequently sold Ordinary Shares are as follows:

Director	No. Share Options exercised	No. Ordinary Shares sold	Resultant interest in Ordinary Shares	Resultant interest in Ordinary Shares as a % of ISC
Phil Reason, CEO	23,429	23,429	770,714	3.39%
Nigel Goldsmith, CFO	15,000	15,000	10,000	0.04%

Issue of Equity and Admission

Application will be made to the London Stock Exchange for the admission of the 61,404 new Ordinary Shares to trading on AIM ("New Ordinary Shares"). Admission is expected to take place at 8.00 a.m. on 10 January 2023.  

Total voting rights

Following the issue and allotment of the above New Ordinary Shares, the Company's issued share capital comprises 22,765,712 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Therefore the total number of voting rights in the Company is 22,765,712.

The figure of 22,765,712 may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change of their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information, please contact:

Instem plc	via Walbrook
Singer Capital Markets (Nominated Adviser & Joint Broker)	[phone]
Peter Steel Alex Bond
Oliver Platts Stifel Nicolaus Europe Limited (Joint Broker)	[phone]
Ben Maddison
Alex Price
Walbrook Financial PR	[phone]
Tom Cooper	[e-mail]
Nick Rome

About Instem  

Instem is a leading provider of IT solutions & services to the life sciences market delivering compelling solutions for Study Management, Regulatory Submissions, Clinical Trial Acceleration, and Informatics-based Insight Generation.

Instem solutions are in use by over 700 customers worldwide, including all of the largest 25 pharmaceutical companies, enabling clients to bring life enhancing products to market faster. Instem's portfolio of software solutions increases client productivity by automating study-related processes while offering the unique ability to generate new knowledge through the extraction and harmonisation of actionable scientific information.

Instem products and services address aspects of the entire drug development value chain, from discovery through to market launch. Management estimate that over 50% of all drugs on the market have been through some part of Instem's platform during their development.

To learn more about Instem solutions and its mission, please visit  www.instem.com

Notification and public disclosure of transactions by persons discharging managerial responsibilities ("PDMRs") and persons closely associated with them

The information set out below is provided in accordance with the requirements of Article 19(3) of the EU Market Abuse Regulation No 596/2014.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Phil Reason
2	Reason for the notification
a)	Position/status	CEO
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Instem plc
b)	LEI	213800PILYUFNNROQX68
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares of 10p each
	Identification code	GB00B3TQCK30
b)	Nature of the transaction	1.  Exercise of Options 2.  Sale of Ordinary Shares
c)	Price(s) and volume(s)
			Price	Volume(s)
			1.  90p per Ordinary Share (exercise price)	23,429
			2.  700p per Ordinary Share (sale price)	23,429
d)	Aggregated information	n/a - the exercise of options over Ordinary Shares and the sale of Ordinary Shares each completed as single transactions
	- Aggregated volume
	- Price
e)	Date of the transaction	4 January 2023
f)	Place of the transaction	In respect of the exercise of options over Ordinary Shares: outside a trading venue In respect of the sale of Ordinary Shares: London Stock Exchange, AIM Market (XLON)

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Nigel Goldsmith
2	Reason for the notification
a)	Position/status	CFO
b)	Initial notification /Amendment	Initial
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	Instem plc
b)	LEI	213800PILYUFNNROQX68
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary shares of 10p each
	Identification code	GB00B3TQCK30
b)	Nature of the transaction	1.  Exercise of Options 2.  Sale of Ordinary Shares
c)	Price(s) and volume(s)
			Price	Volume(s)
			1.  90p per Ordinary Share (exercise price)	15,000
			2.  700p per Ordinary share (sale price)	15,000
d)	Aggregated information	n/a - the exercise of options over Ordinary Shares and the sale of Ordinary Shares each completed as single transactions
	- Aggregated volume
	- Price
e)	Date of the transaction	4 January 2023
f)	Place of the transaction	In respect of the exercise of options over Ordinary Shares: outside a trading venue In respect of the sale of Ordinary Shares: London Stock Exchange, AIM Market (XLON)

 

END

 

 

DSHUPUPCGUPWGMC